Aridis Pharmaceuticals Inc. (ARDS) financial statements (2021 and earlier)

Company profile

Business Address 983 UNIVERSITY AVENUE, BLDG. B
LOS GATOS, CA 95032
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments82124
Cash and cash equivalents82124
Receivables  2
Capitalized contract cost22 
Other undisclosed current assets332
Total current assets:132628
Noncurrent Assets
Property, plant and equipment111
Long-term investments and receivables 01
Long-term investments 01
Intangible assets, net (including goodwill)000
Intangible assets, net (excluding goodwill)000
Capitalized contract cost, net01 
Restricted cash and investments1  
Other noncurrent assets011
Total noncurrent assets:223
TOTAL ASSETS:152832
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities355
Accounts payable222
Accrued liabilities133
Deferred revenue1915
Debt0  
Contract with customer, liability0
Other liabilities0  
Total current liabilities:22195
Noncurrent Liabilities
Long-term debt and lease obligation0  
Long-term debt, excluding current maturities0  
Liabilities, other than long-term debt15 
Deferred revenue15
Other liabilities0  
Total noncurrent liabilities:15 
Total liabilities:24245
Stockholders' equity
Stockholders' equity attributable to parent(9)426
Common stock000
Additional paid in capital11410497
Accumulated deficit(123)(101)(71)
Total stockholders' equity:(9)426
TOTAL LIABILITIES AND EQUITY:152832

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Gross profit:113
Operating expenses(23)(30)(27)
Operating loss:(22)(29)(24)
Loss from continuing operations before equity method investments, income taxes:(22)(29)(24)
Loss from equity method investments(0)(1)(0)
Loss before gain (loss) on sale of properties:(22)(30)(24)
Other undisclosed net income002
Net loss attributable to parent:(22)(30)(22)
Preferred stock dividends and other adjustments  (1)
Net loss available to common stockholders, diluted:(22)(30)(23)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
Net loss:(22)(30)(22)
Comprehensive loss, net of tax, attributable to parent:(22)(30)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: